ストックスクリーナーアプリを入手
2.74
0.36%
-0.010
前日終値:
$2.75
開ける：
$2.77
24時間の取引高:
247.61K
Relative Volume:
0.80
時価総額：
$106.51M
収益：
$2.76M
当期純損益:
$-49.12M
株価収益率:
-1.8267
EPS:
-1.5
ネットキャッシュフロー:
$-46.21M
1週間 パフォーマンス:
-1.44%
1か月 パフォーマンス:
-22.16%
6か月 パフォーマンス:
-48.20%
1年 パフォーマンス:
-50.63%
1日の値動き範囲:
$2.71
$2.84
1週間の範囲:
$2.43
$3.12
52週間の値動き範囲:
$2.43
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
名前
Orchestra Biomed Holdings Inc
セクター
電話
646-343-9298
住所
150 UNION SQUARE DRIVE, NEW HOPE
OBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.74 | 106.51M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | BTIG Research | Buy |
| 2025-01-02 | 開始されました | Barclays | Overweight |
| 2024-08-22 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-25 | 開始されました | B. Riley Securities | Buy |
| 2024-01-19 | 開始されました | Jefferies | Buy |
| 2023-02-24 | 開始されました | Piper Sandler | Overweight |
| 2023-02-07 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Orchestra Biomed Holdings Inc (OBIO) 最新ニュース
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - GlobeNewswire
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed stock holds Buy rating, $12 target from H.C. Wainwright - Investing.com Canada
Financial Metrics Unveiled: Orchestra BioMed Holdings Inc (OBIO)’s Key Ratios in the Spotlight - DWinneX
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy - MSN
When (OBIO) Moves Investors should Listen - news.stocktradersdaily.com
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting - Investing News Network
Orchestra BioMed Hosts Symposium on Breakthrough AVIM Therapy for Uncontrolled Hypertension at HRS 2025 Annual Meeting - Nasdaq
FDA Breakthrough Therapy for 7.7M Hypertension Patients: New Clinical Data | OBIO Stock News - Stock Titan
Examining the Potential Price Growth of Orchestra BioMed Holdings Inc (OBIO) - knoxdaily.com
Investors Take Advantage Of 0.70% Gain In Orchestra BioMed Holdings Inc (NASDAQ: OBIO) - Stocksregister
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy By Investing.com - Investing.com Canada
Orchestra BioMed Holdings Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
There Are Mixed Signals on the Chart for Orchestra BioMed Holdings Inc (OBIO) - uspostnews.com
FDA grants breakthrough status to Orchestra BioMed’s AVIM therapy - Investing.com Australia
Orchestra BioMed shares surge on FDA breakthrough designation By Investing.com - Investing.com Nigeria
Orchestra BioMed (OBIO) Gains FDA Breakthrough Device Status for AVIM Therapy | OBIO Stock News - GuruFocus
Orchestra BioMed shares surge on FDA breakthrough designation - Investing.com Australia
Orchestra BioMed Receives FDA Breakthrough Device Designation for Atrioventricular Interval Modulation Therapy to Address Uncontrolled Hypertension - Nasdaq
Orchestra BioMed (OBIO) Receives FDA Breakthrough Device Designation for AVIM Therapy - StreetInsider
Orchestra's Revolutionary Blood Pressure Device Earns FDA Breakthrough Status: 7.7M Patients Could Benefit - Stock Titan
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
Orchestra BioMed’s Strategic Advances in Medical Innovations - TipRanks
Orchestra Biomed Holdings Inc (OBIO) 財務データ
収益
当期純利益
現金流量
EPS
Orchestra Biomed Holdings Inc (OBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 29 '25 |
Buy |
2.53 |
50,000 |
126,500 |
8,256,163 |
| Aryeh Jason | Director |
Dec 27 '24 |
Option Exercise |
4.30 |
11,700 |
50,310 |
80,060 |
| Hochman David P | See Remarks |
Dec 23 '24 |
Buy |
4.66 |
4,000 |
18,640 |
579,498 |
| Taylor Andrew Lawrence | Chief Financial Officer |
Dec 19 '24 |
Buy |
4.83 |
1,000 |
4,830 |
344,960 |
| Hochman David P | See Remarks |
Dec 18 '24 |
Buy |
4.91 |
5,000 |
24,550 |
575,498 |
| Hochman David P | See Remarks |
Sep 25 '24 |
Buy |
4.75 |
7,500 |
35,630 |
335,002 |
| Hochman David P | See Remarks |
Sep 24 '24 |
Buy |
4.91 |
2,500 |
12,275 |
570,498 |
| Sherman Darren | See Remarks |
Sep 09 '24 |
Sale |
5.48 |
6,804 |
37,286 |
772,691 |
| Sherman Darren | See Remarks |
Sep 10 '24 |
Sale |
5.31 |
6,904 |
36,660 |
765,787 |
| Fain Eric S | Director |
Sep 06 '24 |
Sale |
5.64 |
2,000 |
11,280 |
44,810 |
0.47%
2.63%
大文字化:
|
ボリューム (24 時間):